Elucidation of binding sites of dual antagonists in the human chemokine receptors CCR2 and CCR5

Molecular Pharmacology

Volumn 75, Issue 6, 2009, Pages 1325-1336

  Hall, Spencer E ^a   Mao, Allen ^a   Nicolaidou, Vicky ^b   Finelli, Mattea ^b   Wise, Emma L ^b   Nedjai, Belinda ^b   Kanjanapangka, Julie ^a   Harirchian, Paymann ^c   Chen, Deborah ^c   Selchau, Victor ^c   Ribeiro, Sofia ^c   Schyler, Sabine ^c   Pease, James E ^b   Horuk, Richard ^c   Vaidehi, Nagarajan ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^b NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^c BAYER AG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR ANTAGONIST; CHEMOKINE RECEPTOR CCR2; CHEMOKINE RECEPTOR CCR5; HISTIDINE; ISOLEUCINE; MONOCYTE CHEMOTACTIC PROTEIN 1; MUTANT PROTEIN; N (CARBAMOYLMETHYL) 3 TRIFLUOROMETHYLBENZAMIDO 4 CHLOROBENZYL 3 AMINOPYRROLIDINE; N [4 [[[6,7 DIHYDRO 2 (4 METHYLPHENYL) 5H BENZOCYCLOHEPTEN 8 YL]CARBONYL]AMINO]BENZYL] N,N DIMETHYL 2H TETRAHYDROPYRAN 4 AMINIUM CHLORIDE; THREONINE; TRYPTOPHAN; UNCLASSIFIED DRUG;

ARTICLE; BINDING SITE; CELL SURFACE; CHEMOTAXIS; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFICACY; DRUG RECEPTOR BINDING; HUMAN; HUMAN CELL; IC 50; ISOTOPE LABELING; MUTATIONAL ANALYSIS; POINT MUTATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN STRUCTURE; VALIDATION STUDY;

AMIDES; ANIMALS; BENZAMIDES; BINDING SITES; BINDING, COMPETITIVE; CELL LINE, TUMOR; CHEMOTAXIS; HUMANS; MICE; MODELS, MOLECULAR; POINT MUTATION; PROTEIN CONFORMATION; PYRROLIDINES; QUATERNARY AMMONIUM COMPOUNDS; RADIOLIGAND ASSAY; RECEPTORS, CCR2; RECEPTORS, CCR5;

EID: 66849115400     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.108.053470     Document Type: Article

References (39)

1. Allen SJ, Crown SE, and Handel TM (2007) Chemokine: receptor, structure, interactions and antagonism. Annu Rev Immunol 25:787-820. (Pubitemid 46697924)
2. Baba M, Nishimura O, Kanzaki N, Okamoto M, Sawada H, Iizawa Y, Shiraishi M, Aramaki Y, Okonogi K, Ogawa Y, et al. (1999) A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity. Proc Natl Acad Sci U S A 96:5698-5703. (Pubitemid 29234681)
3. Ballesteros J and Weinstein J (1995) Integrated methods for modeling G-protein coupled receptors. Methods Neurosci 25:366-428.
4. Berkhout TA, Blaney FE, Bridges AM, Cooper DG, Forbes IT, Gribble AD, Groot PH, Hardy A, Ife RJ, Kaur R, et al. (2003) CCR2: characterization of the antagonist binding site from a combined receptor modeling/mutagenesis approach. J Med Chem 46:4070-4086. (Pubitemid 37122451)
5. Bhattacharya S, Hall SE, and Vaidehi N (2008) Agonist-induced conformational changes in bovine rhodopsin: insight into activation of G-protein-coupled receptors. J Mol Biol 382:539-555.
6. Charo IF, Myers SJ, Herman A, Franci C, Connolly AJ, and Coughlin SR (1994) Molecular cloning and functional expression of two monocyte chemoattractant protein 1 receptors reveals alternative splicing of the carboxyl-terminal tails. Proc Natl Acad Sci U S A 91:2752-2756. (Pubitemid 24139426)
7. Charo IF and Ransohoff RM (2006) The many roles of chemokines and chemokine receptors in inflammation. N Engl J Med 354:610-621.
8. Cherezov V, Rosenbaum DM, Hanson MA, Rasmussen SG, Thian FS, Kobilka TS, Choi HJ, Kuhn P, Weis WI, Kobilka BK, et al. (2007) High-resolution crystal structure of an engineered human beta2-adrenergic G protein-coupled receptor. Science 318:1258-1265. (Pubitemid 350172884)
9. Daugherty BL, Siciliano SJ, and Springer MS (2000) Radiolabeled chemokine binding assays. Methods Mol Biol 138:129-134.
10. de Mendonça FL, da Fonseca PC, Phillips RM, Saldanha JW, Williams TJ, and Pease JE (2005) Site-directed mutagenesis of CC chemokine receptor 1 reveals the mechanism of action of UCB 35625, a small molecule chemokine receptor antagonist. J Biol Chem 280:4808-4816.
11. Doms RW and Peiper SC (1997) Unwelcomed guests with master keys: how HIV uses chemokine receptors for cellular entry. Virology 235:179-190. (Pubitemid 27394330)
12. Dragic T, Trkola A, Thompson DA, Cormier EG, Kajumo FA, Maxwell E, Lin SW, Ying W, Smith SO, Sakmar TP, et al. (2000) A binding pocket for a small molecule inhibitor of HIV-1 entry within the transmembrane helices of CCR5. Proc Natl Acad Sci U S A 97:5639-5644. (Pubitemid 30313771)
13. Frantz S (2005) Drug discovery: playing dirty. Nature 437:942-943.
14. Gallivan JP and Dougherty DA (1999) Cation-pi interactions in structural biology. Proc Natl Acad Sci U S A 96:9459-9464.
15. Ghosh A, Rapp CS, and Friesner RA (1998) Generalized Born model based on a surface integral formulation. J Phys Chem B 102:10983-10990. (Pubitemid 128716615)
16. Gong JH and Clark-Lewis I (1995) Antagonists of monocyte chemoattractant protein 1identified by modification of functionally critical NH2-terminal residues. J Exp Med 181:631-640.
17. Govaerts C, Bondue A, Springael JY, Olivella M, Deupi X, Le Poul E, Wodak SJ, Parmentier M, Pardo L, and Blanpain C (2003) Activation of CCR5 by Chemokines Involves an Aromatic Cluster between Transmembrane Helices 2 and 3. J Biol Chem 278:1892-1903. (Pubitemid 36801429)
18. Hall SE (2005) Development of structure prediction methods for G-protein coupled receptors, Ph.D. Thesis, California Institute of Technology, Pasadena, CA.
19. Heo J, Vaidehi N, Wendel J, and Goddard WA 3rd (2007) Prediction of the 3D structure of rat MrgA GPCR and identification of its binding site. J Mol Graph Model 26:800-812.
20. Jaakola VP, Griffith MT, Hanson MA, Cherezov V, Chien EY, Lane JR, IJzerman AP, and Stevens RC (2008) The 2.6 angstrom crystal structure of a human A2A adenosine receptor bound to an antagonist. Science 322:1211-1217.
21. Jarnagin K, Grunberger D, Mulkins M, Wong B, Hemmerich S, Paavola C, Bloom A, Bhakta S, Diehl F, Freedman R, et al. (1999) Identification of surface residues of the monocyte chemotactic protein 1 that affect signaling through the receptor CCR2. Biochemistry 38:16167-16177. (Pubitemid 129520537)
22. Lieberman-Blum SS, Fung HB, and Bandres JC (2008) Maraviroc: a CCR5-receptor antagonist for the treatment of HIV-1 infection. Clin Ther 30:1228-1250.
23. Maeda K, Das D, Ogata-Aoki H, Nakata H, Miyakawa T, Tojo Y, Norman R, Takaoka Y, Ding J, Arnold GF, et al. (2006) Structural and molecular interactions of CCR5 inhibitors with CCR5. J Biol Chem 281:12688-12698. (Pubitemid 43855359)
24. Mirzadegan T, Diehl F, Ebi B, Bhakta S, Polsky I, McCarley D, Mulkins M, Weatherhead GS, Lapierre JM, Dankwardt J, et al. (2000) Identification of the binding site for a novel class of CCR2b chemokine receptor antagonists-binding to a common chemokine receptor motif within the helical bundle. J Biol Chem 275:25562-25571. (Pubitemid 30658810)
25. Moree WJ, Kataoka K, Ramirez-Weinhouse MM, Shiota T, Imai M, Tsutsumi T, Sudo M, Endo N, Muroga Y, Hada T, et al. (2008) Potent antagonists of the CCR2b receptor. Part 3: SAR of the (R)-3-aminopyrrolidine series. Bioorg Med Chem Lett 18:1869-1873.
26. Morphy R and Rankovic Z (2005) Designed multiple ligands. An emerging drug discovery paradigm. J Med Chem 48:6523-6543. (Pubitemid 41504710)
27. Murphy PM (1994) The molecular biology of leukocyte chemoattractant receptors. Annu Rev Immunol 12:593-633. (Pubitemid 24140426)
28. Palczewski K, Kumasaka T, Hori T, Behnke CA, Motoshima H, Fox BA, Le Trong I, Teller DC, Okada T, Stenkamp RE, et al. (2000) Crystal structure of rhodopsin: A G protein-coupled receptor. Science 289:739-745. (Pubitemid 30650186)
29. Ribeiro S and Horuk R (2005) Chemokine Receptor Antagonists: From the Bench to the Clinic. Wiley-VCH, Weinheim, Germany.
30. Samson M, Labbe O, Mollereau C, Vassart G, and Parmentier M (1996) Molecular cloning and functional expression of a new human CC-chemokine receptor gene. Biochemistry 35:3362-3367. (Pubitemid 26092558)
31. Schertler GFX (1998) Structure of rhodopsin. Eye 12:504-510. (Pubitemid 28356658)
32. Seibert C, Ying W, Gavrilov S, Tsamis F, Kuhmann SE, Palani A, Tagat JR, Clader JW, McCombie SW, Baroudy BM, et al. (2006) Interaction of small molecule inhibitors of HIV-1 entry with CCR5. Virology 349:41-54.
33. Stroke IL, Cole AG, Simhadri S, Brescia MR, Desai M, Zhang JJ, Merritt JR, Appell KC, Henderson I, and Webb ML (2006) Identification of CXCR3 receptor agonists in combinatorial small-molecule libraries. Biochem Biophys Res Commun 349:221-228. (Pubitemid 44331785)
34. Szekanecz Z, Szücs G, Szántó S, and Koch AE (2006) Chemokines in rheumatic diseases. Curr Drug Targets 7:91-102.
35. Trabanino RJ, Hall SE, Vaidehi N, Floriano WB, Kam VW, and Goddard WA 3rd (2004) First Principles Prediction of the structure and Function of G protein-coupled receptors: validation for bovine rhodopsin. Biophys J 86:1904-1921.
36. Vaidehi N, Schlyer S, Trabanino RJ, Floriano WB, Abrol R, Sharma S, Kochanny M, Koovakat S, Dunning L, Liang M, et al. (2006) Predictions of CCR1 chemokine receptor structure and BX 471 antagonist binding followed by experimental validation. J Biol Chem 281:27613-27620. (Pubitemid 44401786)
37. Vriend G (1990) WHAT IF - a molecular modeling and drug design program. J Mol Graph 8:52-56, 29.
38. Wise EL, Duchesnes C, da Fonseca PC, Allen RA, Williams TJ, and Pease JE (2007) Small molecule receptor agonists and antagonists of CCR3 provide insight into mechanisms of chemokine receptor activation. J Biol Chem 282:27935-27943.
39. Zhang Y and Rollins BJ (1995) A dominant negative inhibitor indicates that monocyte chemoattractant protein 1 functions as a dimer. Mol Cell Biol 15:4851-4855.